Spotlight on Infectious Diseases

Credits: 0.50 CME / MOC
Incorporating Influenza Treatment Paradigms that Reduce Complications: A Wheel of Knowledge Challenge
John J. Russell, MD, FAAFP
Vindico

Incorporating Influenza Treatment Paradigms that Reduce Complications: A Wheel of Knowledge Challenge

Start

Activity Details

Free CME/MOC
0.50 AMA PRA Category 1 Credit(s)™/
ABIM/AAFP/AANP/AAPA
Released: January 15, 2021
Expires: January 14, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family practice physicians, internists, pediatricians, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Diagnose patients with influenza infection by using guideline recommendations and best practices.
  • Distinguish antiviral treatments for influenza based on their efficacy, safety, and ability to reduce viral shedding.
  • Select the most appropriate treatment for patients diagnosed with influenza who are at normal or high risk for complications.
  • Assess the use of antiviral prophylaxis in people who have been exposed to influenza infection.

Activity Description

While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. Antivirals with different targets as well as different mechanisms of action provide multiple therapeutic options, and hold promise in improving treatment effectiveness. Family physicians and advanced practice clinicians are integral for the expedient management of patients with flu. In this Wheel of Knowledge Challenge, your knowledge will be tested on the latest updates in diagnosing and managing influenza.

Activity Chair

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosure
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

The AAFP has reviewed Incorporating Influenza Treatment Paradigms that Reduce Complications: A Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 1/15/2021 to 1/14/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid from 1/15/2021 to 1/14/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201758.

This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.33 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20124677. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This enduring material is approved for 1 year from the date of original release, January 15, 2021 through January 14, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AANP Contact Hours Certificate, or AAPA Category 1 CME Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Free CME/MOC
0.50 AMA PRA Category 1 Credit(s)™/
ABIM/AAFP/AANP/AAPA
Released: January 15, 2021
Expires: January 14, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family practice physicians, internists, pediatricians, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Diagnose patients with influenza infection by using guideline recommendations and best practices.
  • Distinguish antiviral treatments for influenza based on their efficacy, safety, and ability to reduce viral shedding.
  • Select the most appropriate treatment for patients diagnosed with influenza who are at normal or high risk for complications.
  • Assess the use of antiviral prophylaxis in people who have been exposed to influenza infection.

Activity Description

While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. Antivirals with different targets as well as different mechanisms of action provide multiple therapeutic options, and hold promise in improving treatment effectiveness. Family physicians and advanced practice clinicians are integral for the expedient management of patients with flu. In this Wheel of Knowledge Challenge, your knowledge will be tested on the latest updates in diagnosing and managing influenza.

Activity Chair

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosure
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

The AAFP has reviewed Incorporating Influenza Treatment Paradigms that Reduce Complications: A Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 1/15/2021 to 1/14/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid from 1/15/2021 to 1/14/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201758.

This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.33 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20124677. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This enduring material is approved for 1 year from the date of original release, January 15, 2021 through January 14, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AANP Contact Hours Certificate, or AAPA Category 1 CME Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Infectious Diseases Presentations

0.75 CME / MOC / CNE / CPE
RMEI Medical Education, LLC
Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum℠

Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum℠

Start

Activity Details

Free CME/MOC/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Slieagen, Takeda (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

Activity Details

Free CME/MOC/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Slieagen, Takeda (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

1.00 AAPA / CME / CPE
Vindico
Non-tuberculous Mycobacterial Lung Disease (NTM-LD): New Guidelines to Manage a Challenging Respiratory Disease

Non-tuberculous Mycobacterial Lung Disease (NTM-LD): New Guidelines to Manage a Challenging Respiratory Disease

Start

Activity Details

Free CME/CPE/AAPA
1.0 AMA PRA Category 1 Credit(s)
1.0 ACPE Contact Hour(s)
1.0 AAPA Category 1 CME Credits
Released: May 31, 2021
Expires: May 30, 2022
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with non-tuberculous mycobacterial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Identify patients with non-tuberculous mycobacterial lung disease (NTM-LD) using knowledge of pathophysiology, environmental factors, underlying conditions (eg, bronchiectasis), and risk factors.
  • Review the newly updated guideline recommendations for the diagnosis and treatment of NTM-LD.
  • Examine the strategies to manage adverse effects associated with treatment of NTM-LD including approaches to improve treatment adherence.

Activity Description

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. A range of clinical manifestations can arise from NTM infection. Pulmonary disease is the most common of these manifestations, often occurring in patients with underlying lung diseases, such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults, with the potential for chronic infection requiring long-term treatment and the potential for significant side effects. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and provide care informed by the latest clinical evidence and updated practice guidelines. In this educational activity, faculty will review pathophysiology of and risk factors for NTM, evidence-based guidelines for diagnosis and treatment, and strategies for managing adverse effects associated with NTM treatment regimens.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 1.0 contact hour of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-009-H01-P, effective 05/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

Accreditation Council for Pharmacy EducationThis activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1AAPA Category 1 CME credits. Approval is valid from 5/31/2021 to 5/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202737.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed Incorporated.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE/AAPA
1.0 AMA PRA Category 1 Credit(s)
1.0 ACPE Contact Hour(s)
1.0 AAPA Category 1 CME Credits
Released: May 31, 2021
Expires: May 30, 2022
60 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with non-tuberculous mycobacterial lung disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Identify patients with non-tuberculous mycobacterial lung disease (NTM-LD) using knowledge of pathophysiology, environmental factors, underlying conditions (eg, bronchiectasis), and risk factors.
  • Review the newly updated guideline recommendations for the diagnosis and treatment of NTM-LD.
  • Examine the strategies to manage adverse effects associated with treatment of NTM-LD including approaches to improve treatment adherence.

Activity Description

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. A range of clinical manifestations can arise from NTM infection. Pulmonary disease is the most common of these manifestations, often occurring in patients with underlying lung diseases, such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults, with the potential for chronic infection requiring long-term treatment and the potential for significant side effects. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and provide care informed by the latest clinical evidence and updated practice guidelines. In this educational activity, faculty will review pathophysiology of and risk factors for NTM, evidence-based guidelines for diagnosis and treatment, and strategies for managing adverse effects associated with NTM treatment regimens.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 1.0 contact hour of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-009-H01-P, effective 05/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

Accreditation Council for Pharmacy EducationThis activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1AAPA Category 1 CME credits. Approval is valid from 5/31/2021 to 5/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202737.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed Incorporated.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME
SHM (Society of Hospital Medicine)
Hospitalists Guide to COVID-19

Hospitalists Guide to COVID-19

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: May 4, 2021
Expires: May 3, 2022
60 minutes to complete

Accredited By

Target Audience

Hospitalists (all hospital clinicians treating patients with COVID-19)

Learning Objectives

  1. Discuss the findings from randomized clinical trials for treatments for hospitalized patients
  2. Evaluate current guidance for treatment of patients requiring hospitalization

Activity Description

Webinar featuring a panelist of hospitalists and infectious disease experts review up-to-date information on clinical staging, progression, and current management of COVID-19, including updates on coagulopathy.

Agenda

  • Hospital Medicine: COVID-19 Treatment and Clinical Care
  • Clinical Management & Coagulopathy Updates
  • COVID-19 Therapeutics for Hospitalized Patients

Course Director

Ebrahim Barkoudah, MD, MPH, FACP, SFHM
Associate Director of Hospital Medicine Unit
Medical Director of Department of Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; and Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities. Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Expert Speakers

William Garneau, MD, MPH
Assistant Professor of Medicine
Division of Hospital Medicine
Johns Hopkins Hospital
Baltimore, MD

Stock: J&J, AstraZeneca.

Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director
Division of Infectious Diseases
Johns Hopkins Hospital
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Ownership equity: JNJ. Scientific Consulting: Verily, EMD Serono. DMSB: Humanigen.

Moderators

Ramesh Adhikari, MD, MS, SFHM
Hospitalist/Geriatrician
Society of Hospital Medicine (SHM) Indiana Chapter
President
Franciscan Health Lafayette East Hospital
Lafayette, IN

Jose Mercado, MD, MPH
Hospital Epidemiologist
Dartmouth-Hitchcock
Assistant Professor of Medicine
Geisel School of Medicine
Medical Director
Alice Peck Day Hospital
Lebanon, NH

Conflict of Interest Policy/Disclosure Statement

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

Accreditation Statement

The Society of Hospital Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity. This activity is classified as non-variable credit. The entire module must be completed to receive credit.

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy, and research.

Statement of Commercial Support

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The presenters have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in ongoing studies, including tocilizumab, dexamethasone, and COVID-19 convalescent plasma.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: May 4, 2021
Expires: May 3, 2022
60 minutes to complete

Accredited By

Target Audience

Hospitalists (all hospital clinicians treating patients with COVID-19)

Learning Objectives

  1. Discuss the findings from randomized clinical trials for treatments for hospitalized patients
  2. Evaluate current guidance for treatment of patients requiring hospitalization

Activity Description

Webinar featuring a panelist of hospitalists and infectious disease experts review up-to-date information on clinical staging, progression, and current management of COVID-19, including updates on coagulopathy.

Agenda

  • Hospital Medicine: COVID-19 Treatment and Clinical Care
  • Clinical Management & Coagulopathy Updates
  • COVID-19 Therapeutics for Hospitalized Patients

Course Director

Ebrahim Barkoudah, MD, MPH, FACP, SFHM
Associate Director of Hospital Medicine Unit
Medical Director of Department of Medicine
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute; Bristol Myers Squibb; and Janssen. Payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities. Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer, and Portola/Alexion.

Expert Speakers

William Garneau, MD, MPH
Assistant Professor of Medicine
Division of Hospital Medicine
Johns Hopkins Hospital
Baltimore, MD

Stock: J&J, AstraZeneca.

Paul G. Auwaerter, MD, MBA, FIDSA
Clinical Director
Division of Infectious Diseases
Johns Hopkins Hospital
Past President of the Infectious Diseases Society of America (IDSA)
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Ownership equity: JNJ. Scientific Consulting: Verily, EMD Serono. DMSB: Humanigen.

Moderators

Ramesh Adhikari, MD, MS, SFHM
Hospitalist/Geriatrician
Society of Hospital Medicine (SHM) Indiana Chapter
President
Franciscan Health Lafayette East Hospital
Lafayette, IN

Jose Mercado, MD, MPH
Hospital Epidemiologist
Dartmouth-Hitchcock
Assistant Professor of Medicine
Geisel School of Medicine
Medical Director
Alice Peck Day Hospital
Lebanon, NH

Conflict of Interest Policy/Disclosure Statement

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.

Accreditation Statement

The Society of Hospital Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in this activity. This activity is classified as non-variable credit. The entire module must be completed to receive credit.

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy, and research.

Statement of Commercial Support

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The presenters have indicated that they will be referencing the unlabeled or unapproved use of agents currently being investigated in ongoing studies, including tocilizumab, dexamethasone, and COVID-19 convalescent plasma.

0.75 CME / CNE / CPE
Global Education Group
HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 1: Rapid ART Initiation: A Key Strategy for Ending the HIV Epidemic

HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 1: Rapid ART Initiation: A Key Strategy for Ending the HIV Epidemic

Start

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 1, we introduce the central role rapid ART initiation can play in ending the HIV epidemic. This strategy has demonstrated increased immediate ART uptake and decreased time to viral suppression and holds hope for reducing HIV transmission risk, community viral load, and inequities in ART access. Part 1 will present programs that model successful rapid-ART implementation within different care-delivery systems and patient populations.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-184-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 1, we introduce the central role rapid ART initiation can play in ending the HIV epidemic. This strategy has demonstrated increased immediate ART uptake and decreased time to viral suppression and holds hope for reducing HIV transmission risk, community viral load, and inequities in ART access. Part 1 will present programs that model successful rapid-ART implementation within different care-delivery systems and patient populations.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-20-184-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

0.75 CME / CNE / CPE
Global Education Group
HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 2: Overcoming Barriers: Successful Rapid ART Initiation

HIV Experts & Evidence™: A Two-Part Continuing Medical Education Series on the Evolving Models of HIV Care – Part 2: Overcoming Barriers: Successful Rapid ART Initiation

Start

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 2, we will address common real-world barriers to rapid-ART implementation at the levels of systems, clinics, providers, and patients. We will then review guideline-based antiretroviral selection in the Rapid ART context and show how you can move beyond perceived barriers to quickly and safely initiate ART and achieve viral suppression.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-051-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 Contact Hour(s)
Released: May 4, 2021
Expires: May 4, 2022
45 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity is intended for infectious diseases and human immunodeficiency virus (HIV)-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objectives

  • Reduce time from HIV diagnosis to viral suppression to improve patient outcomes and prevent HIV transmission
  • Select appropriate regimens for rapid ART initiation based on current guidelines and patient characteristics
  • Implement strategies designed to decrease barriers to the provision of rapid ART to patients with newly diagnosed HIV infection

Activity Description

In Part 2, we will address common real-world barriers to rapid-ART implementation at the levels of systems, clinics, providers, and patients. We will then review guideline-based antiretroviral selection in the Rapid ART context and show how you can move beyond perceived barriers to quickly and safely initiate ART and achieve viral suppression.

Statement of Educational Need

Guideline-based rapid initiation of antiretroviral therapy (ART) for treatment of HIV is now the standard of care.1 Best-practice rapid ART protocols promote immediate linkage to HIV care, decreased time to ART initiation, decreased time to viral suppression (VS), and long-term VS—even within vulnerable populations.2 Shorter time to VS is associated with decreases in the incidence of both AIDS- and non-AIDS–related events.3 It further benefits the individual’s partners and at-risk populations by decreasing the period of time during which the virus is transmittable. This informs the Undetectable Equals Untransmittable (U=U) initiative, which serves not only the public health goal of ending the HIV/AIDS pandemic, but also brings equity to HIV care for vulnerable populations.4 Geared to the needs of HIV-specialist clinicians, this two-part HIV Experts and Evidence™ enduring activity will address rapid ART guidelines, provide practical solutions to systemic and clinical barriers that can impede access to rapid ART regimens and retention in care, and real-world approaches to enhanced patient-centered services.

References

  1. U.S. Department of Health and Human Services. Guidelines for Use of Antiretroviral Agents in HIV-1−Infected Adults and Adolescents Living with HIV. Last updated July 2020. https://aidsinfo.nih.gov/guidelines. Accessed August 24, 2020.
  2. Coffey S, et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population AIDS. 2019;33(5):825-832.
  3. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.
  4. Eisinger RW, et al. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321(5):451-452.

Faculty

Jonathan A. Colasanti, MD, MSPH
Associate Professor of Medicine
Emory University School of Medicine
Medical Director, Infectious Diseases Program
Grady Health System
Atlanta, Georgia


Jason Halperin, MD, MPH
Assistant Professor of Medicine
Tulane University School of Medicine
HIV/ID Clinician Lead, CrescentCare
New Orleans, Louisiana

Disclosure of Conflicts of Interest

Global requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Jonathan A. Colasanti, MD, MSPH - Nothing to disclose
Jason Halperin, MD, MPH - Nothing to disclose

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Ashley Marostica, RN, MSN - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Jeanette Ruby, MD - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 0.75 contact hour(s) is provided by Global. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Accreditation Council for Pharmacy EducationGlobal is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation
Global designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-051-H02-P).

This is a knowledge-based activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score 75% or better on the posttest and complete the program evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

0.50 CME / CPE
Vindico
DecisionSim: Enhancing Clinical Decision-making in HIV Management—A 58-Year-Old Woman With HIV and History of Medication Intolerance

DecisionSim: Enhancing Clinical Decision-making in HIV Management—A 58-Year-Old Woman With HIV and History of Medication Intolerance

Start

Activity Details

Free CME/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ACPE Contact Hour(s)
Released: April 30, 2021
Expires: April 29, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the most appropriate antiretroviral therapy (ART) regimens in patients with HIV and comorbidities.
  • Utilize ART regimens that improve outcomes in highly treatment-experienced patients with HIV.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this interactive, case-based program, expert faculty will provide guidance on how to incorporate new treatment strategies into clinical practice as well as treatment modification in highly treatment-experienced patients with multiple comorbidities. This decision simulation case will focus on a 58-year-old woman with HIV, multiple comorbidities, and history of medication intolerance.

Faculty

Eileen Scully, MD, PhD
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure:
Honoraria: Mediahuset

Planning Committee

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure:
Consulting Fee: Genentech, Gilead, Merck
Contracted Research: Gilead, Merck, ViiV

Reviewers:
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure: Contracted Research (Paid to Institution): ViiV

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-007-H02-P, effective 4/30/2021. This is a knowledge-based activity and there is no fee to participate.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, participate in the interactive case, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ACPE Contact Hour(s)
Released: April 30, 2021
Expires: April 29, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the most appropriate antiretroviral therapy (ART) regimens in patients with HIV and comorbidities.
  • Utilize ART regimens that improve outcomes in highly treatment-experienced patients with HIV.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this interactive, case-based program, expert faculty will provide guidance on how to incorporate new treatment strategies into clinical practice as well as treatment modification in highly treatment-experienced patients with multiple comorbidities. This decision simulation case will focus on a 58-year-old woman with HIV, multiple comorbidities, and history of medication intolerance.

Faculty

Eileen Scully, MD, PhD
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure:
Honoraria: Mediahuset

Planning Committee

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure:
Consulting Fee: Genentech, Gilead, Merck
Contracted Research: Gilead, Merck, ViiV

Reviewers:
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure: Contracted Research (Paid to Institution): ViiV

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-007-H02-P, effective 4/30/2021. This is a knowledge-based activity and there is no fee to participate.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, participate in the interactive case, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME / CPE
Vindico
HIV Management: Clinical Case Conundrums – A Wheel of Knowledge Challenge

HIV Management: Clinical Case Conundrums – A Wheel of Knowledge Challenge

Start

Activity Details

Free CME/CPE
0.50 AMA PRA Category 1 Credit(s)
0.50 ACPE Contact Hour(s)
Released: April 23, 2021
Expires: April 22, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate new evidence-based guidelines for the use of antiretroviral (ARV) agents in adults and adolescents with HIV.
  • Initiate treatment in ARV-naive patients, based on individual patient needs, characteristics, preferences, and genotypic drug-resistance testing.
  • Interpret recent evidence regarding the use of antiretroviral therapy (ART) in women of childbearing potential.
  • Incorporate the use of switching ART regimens in patients who have experienced adverse events.
  • Implement the most appropriate regimens in patients with HIV and comorbidities.
  • Recognize the complexities of HIV management in older, highly treatment-experienced patients due to polypharmacy, drug-drug interactions, and other issues.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this Wheel of Knowledge Challenge interactive quiz, your knowledge will be tested on the latest clinical developments and management strategies for patients with HIV as an expert faculty member provides guidance on how to incorporate new treatment strategies into clinical practice. Your host will also discuss various aspects of HIV management, including selection of a patient’s initial antiretroviral regimen, treatment modification in highly treatment-experienced patients, and individualizing therapy.

Faculty

Host:
W. David Hardy, MD

Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Keck School of Medicine of USC
Los Angeles, CA

Disclosure:
Consulting Fee: Enochian BioSciences, Gilead, Merck, ViiV/GlaxoSmithKline

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure:
Contracted Research (Paid to Institution):
ViiV

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and Accreditation Council for Pharmacy Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.50 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-21-008-H02-P, effective 4/23/2021. This is a knowledge-based activity, and there is no fee to attend.

MIPS Qualifying Activity
Vindico has identified this CE activity as an improvement activity in the Merit-based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement MIPS of QPP, accredited CE providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit. Pharmacist learners who submit their NABP ID and DOB will be reported to the CPE Monitor by Vindico Medical Education directly.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE
0.50 AMA PRA Category 1 Credit(s)
0.50 ACPE Contact Hour(s)
Released: April 23, 2021
Expires: April 22, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate new evidence-based guidelines for the use of antiretroviral (ARV) agents in adults and adolescents with HIV.
  • Initiate treatment in ARV-naive patients, based on individual patient needs, characteristics, preferences, and genotypic drug-resistance testing.
  • Interpret recent evidence regarding the use of antiretroviral therapy (ART) in women of childbearing potential.
  • Incorporate the use of switching ART regimens in patients who have experienced adverse events.
  • Implement the most appropriate regimens in patients with HIV and comorbidities.
  • Recognize the complexities of HIV management in older, highly treatment-experienced patients due to polypharmacy, drug-drug interactions, and other issues.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this Wheel of Knowledge Challenge interactive quiz, your knowledge will be tested on the latest clinical developments and management strategies for patients with HIV as an expert faculty member provides guidance on how to incorporate new treatment strategies into clinical practice. Your host will also discuss various aspects of HIV management, including selection of a patient’s initial antiretroviral regimen, treatment modification in highly treatment-experienced patients, and individualizing therapy.

Faculty

Host:
W. David Hardy, MD

Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Keck School of Medicine of USC
Los Angeles, CA

Disclosure:
Consulting Fee: Enochian BioSciences, Gilead, Merck, ViiV/GlaxoSmithKline

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure:
Contracted Research (Paid to Institution):
ViiV

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and Accreditation Council for Pharmacy Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.50 contact hours of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-21-008-H02-P, effective 4/23/2021. This is a knowledge-based activity, and there is no fee to attend.

MIPS Qualifying Activity
Vindico has identified this CE activity as an improvement activity in the Merit-based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement MIPS of QPP, accredited CE providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of 6 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit. Pharmacist learners who submit their NABP ID and DOB will be reported to the CPE Monitor by Vindico Medical Education directly.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at CME@VindicoCME.com

0.50 CME / CPE
Vindico
DecisionSim: Enhancing Clinical Decision-making in HIV Management—A 52-Year-Old Man With HIV and Multiple Comorbidities Presents With Chronic Diarrhea

DecisionSim: Enhancing Clinical Decision-making in HIV Management—A 52-Year-Old Man With HIV and Multiple Comorbidities Presents With Chronic Diarrhea

Start

Activity Details

Free CME/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ACPE Contact Hour(s)
Released: April 21, 2021
Expires: April 20, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the most appropriate antiretroviral therapy (ART) regimens in patients with HIV and comorbidities.
  • Utilize ART regimens that improve outcomes in highly treatment-experienced patients with HIV.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this interactive, case-based program, expert faculty will provide guidance on how to incorporate new treatment strategies into clinical practice as well as treatment modification in highly treatment-experienced patients with multiple comorbidities. This decision simulation case will focus on a 52-year-old man with HIV and multiple comorbidities who presents with chronic diarrhea.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure:
Consulting Fee: Genentech, Gilead, Merck
Contracted Research: Gilead, Merck, ViiV

Planning Committee

Eileen Scully, MD, PhD
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure: No relevant financial relationships to disclose.

Reviewers:
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure: Contracted Research (Paid to Institution): ViiV

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-006-H02-P, effective 4/21/2021. This is a knowledge-based activity and there is no fee to participate.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, participate in the interactive case, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ACPE Contact Hour(s)
Released: April 21, 2021
Expires: April 20, 2022
30 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pharmacists, and other health care professionals involved in the management of patients with HIV.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Incorporate the most appropriate antiretroviral therapy (ART) regimens in patients with HIV and comorbidities.
  • Utilize ART regimens that improve outcomes in highly treatment-experienced patients with HIV.

Activity Description

Antiretroviral therapy has improved dramatically over the past decade. This progress has yielded more treatment choices for clinicians and patients but also adds greater complexity to the already diverse field of HIV treatment. Clinicians must keep apprised of new data regarding treatment strategies, including drug simplification and long-acting injectables, selection of appropriate individualized therapy, and effective management of treatment side effects. In this interactive, case-based program, expert faculty will provide guidance on how to incorporate new treatment strategies into clinical practice as well as treatment modification in highly treatment-experienced patients with multiple comorbidities. This decision simulation case will focus on a 52-year-old man with HIV and multiple comorbidities who presents with chronic diarrhea.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Investigator, Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Disclosure:
Consulting Fee: Genentech, Gilead, Merck
Contracted Research: Gilead, Merck, ViiV

Planning Committee

Eileen Scully, MD, PhD
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Disclosure: No relevant financial relationships to disclose.

Reviewers:
Jennifer Cocohoba, PharmD, MAS, BCPS, AAHIVP
Disclosure: Contracted Research (Paid to Institution): ViiV

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-006-H02-P, effective 4/21/2021. This is a knowledge-based activity and there is no fee to participate.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, participate in the interactive case, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or CPE Statement of Credit.

Statement of Commercial Support

This educational activity is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 AANP / CME
AKH Inc., Advancing Knowledge in Healthcare
PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care

PsA+COVID-19: Virtual Solutions and Personalized Learning That Optimize Psoriatic Arthritis Care

Start

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 Contact Hour(s)
Released: April 12, 2021
Expires: April 12, 2022
75 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

  • Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  • Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
  • Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.

Activity Description

The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.

To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.

Agenda

  1. Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
  2. Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
  3. Personalized Patient Cases
  4. Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time

Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington


Alvin F. Wells, MD, PhD, FACR
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
  • Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Faculty (Presenter): Phillip Mease, MD, MACR

  • Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
  • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB

Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi

Faculty (Planner): Richard Martin, MD, MA

  • Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly

Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP

  • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designated this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
AANPThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 Contact Hour(s)
Released: April 12, 2021
Expires: April 12, 2022
75 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audience for this activity is rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

  • Summarize mechanisms of action (MOAs), effectiveness, and safety of conventional, targeted synthetic, and biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  • Explain reasons to stop/delay treatment vs reasons to initiate/continue PsA treatment in elderly patients and patients with comorbidities in the context of COVID-19.
  • Discuss the role of telemedicine and other virtual strategies and tools to remotely monitor PsA progression and manage patients with PsA during and following the time of the COVID-19 pandemic.

Activity Description

The COVID-19 pandemic has added uncertainty and complexity to providing care to patients with psoriatic disease. Appropriate use of strategies and tools that support providing rheumatology care remotely is critical in today’s clinical encounters. This educational activity addresses these issues through a variety of innovative experiences. First, Dr. Philip Mease and Dr. Alvin Wells present a fascinating look at immune activation and targeted therapies in psoriatic arthritis (PsA) through augmented reality. Participants are invited to join this experience via their mobile device. The activity also features a concise overview of the latest American College of Rheumatology’s clinical practice guidelines related to COVID-19, a self-directed exercise in building and exploring patient cases, and best practices for telemedicine.

To gain the most benefit from participation in this activity, please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device. You may use one of the QR codes below or search for it in the Google Play or App Store. You may also find it helpful to download and print the worksheet from the Resources section before starting the activity.

Agenda

  1. Augmented Reality Experience: The Main Pathways of Immune Activation and Targeted Therapies in Psoriatic Arthritis
  2. Treatment of Psoriatic Arthritis During the COVID-19 Pandemic
  3. Personalized Patient Cases
  4. Telemedicine: Best Practices, and Tools to Overcome the Constraints of Distance, Location, and Time

Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research
Swedish Medical Center/Providence St. Joseph Health
Clinical Professor,
University of Washington School of Medicine
Seattle, Washington


Alvin F. Wells, MD, PhD, FACR
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Director, Aurora Rheumatology and Immunotherapy Center
Franklin, Wisconsin
Adjunct Assistant Professor, Duke University Medical Center
Durham, North Carolina
Assistant Clinical Professor, Medical College of Wisconsin
Milwaukee, Wisconsin

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Leah Johnson, Marianna Shershneva, MD, PhD
  • Faculty (Planner): Linda Grinnell-Merrick, MS, NP-BC
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Faculty (Presenter): Phillip Mease, MD, MACR

  • Consulting Fee: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
  • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB

Faculty (Presenter): Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, Alexion, Aurinia, BMS, Lilly, Novartis, Pfizer, Sanofi

Faculty (Planner): Richard Martin, MD, MA

  • Contracted Research: AbbVie, Eicos Pharmaceutical, Lilly

Faculty (Planner): Atul Deodhar, MD, MRCP, FACR, FACP

  • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Advisory Board: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB
  • Contracted Research: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, UCB

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation Statement

Forefront Collaborative is accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designated this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
AANPThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.25 contact hour(s) (which includes 1.25 hour(s) of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

0.25 AAPA / CME / CPE
Vindico
Optimizing Diagnosis and Management of Nontuberculous Mycobacterial Lung Disease—NTM Lung Disease Curbside Consults: Improving Patient Adherence - Managing Adverse Events

Optimizing Diagnosis and Management of Nontuberculous Mycobacterial Lung Disease—NTM Lung Disease Curbside Consults: Improving Patient Adherence - Managing Adverse Events

Start

Activity Details

Free CME/CPE/AAPA
0.25 AMA PRA Category 1 Credit(s)
0.25 ACPE Contact Hour(s)
0.25 AAPA Category 1 CME Credit(s)
Released: March 31, 2021
Expires: March 30, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with nontuberculous mycobacterial lung disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to examine the strategies to manage adverse effects associated with treatment of NTM-LD, including approaches to improve treatment adherence.

Activity Description

In this Curbside Consult, Drs. Charles Daley and David Griffith discuss strategies for improving treatment adherence and managing medication-related adverse events in a 77-year-old patient with Mycobacterium avium complex lung disease.

Statement of Educational Need

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM infection, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence and guidelines.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hour(s) of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-005-H01-P, effective 03/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25AAPA Category 1 CME Credit(s). Approval is valid from 3/31/2021 to 3/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202344.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/CPE/AAPA
0.25 AMA PRA Category 1 Credit(s)
0.25 ACPE Contact Hour(s)
0.25 AAPA Category 1 CME Credit(s)
Released: March 31, 2021
Expires: March 30, 2022
15 minutes to complete

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, pharmacists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with nontuberculous mycobacterial lung disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to examine the strategies to manage adverse effects associated with treatment of NTM-LD, including approaches to improve treatment adherence.

Activity Description

In this Curbside Consult, Drs. Charles Daley and David Griffith discuss strategies for improving treatment adherence and managing medication-related adverse events in a 77-year-old patient with Mycobacterium avium complex lung disease.

Statement of Educational Need

Nontuberculous mycobacteria (NTM) infection is becoming more widespread in the United States and worldwide. Pulmonary disease is the most common manifestation of NTM infection, often occurring in patients with underlying lung diseases such as cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. A disproportionate number of patients with NTM lung disease are older adults or immunocompromised individuals, with the potential for chronic infection requiring long-term treatment. Therapies with improved efficacy and safety are critical for optimal management of this increasingly prevalent disease. Additionally, education is required to better enable clinicians to make a timely, accurate diagnosis and deliver care informed by the latest clinical evidence and guidelines.

Activity Chair

David E. Griffith, MD, FACP, FCCP, ATSF
Professor of Medicine
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: Insmed
Speakers Bureau: Insmed
Non-CME Service Fees: Insmed
Contracted Research: Insmed

Faculty

Charles L. Daley, MD
Professor of Medicine
National Jewish Health and University of Colorado
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO

Disclosure:
Consulting Fee: AN2, Cipla, Insmed, Matinas, Paratek, Spero
Contracted Research: Insmed

Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Council for Pharmacy EducationVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This program is acceptable for 0.25 contact hour(s) of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-21-005-H01-P, effective 03/31/2021. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.25AAPA Category 1 CME Credit(s). Approval is valid from 3/31/2021 to 3/30/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202344.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Insmed.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages